Early onset pancreatic cancer—exploring contemporary treatment and outcomes using real-world data

期刊论文
发表日期：

2024年3月6日

查看全文

Shehara Mendis,
Lara Lipton,
Yat Hang To,
Sumitra Ananda,
Michael Michael,
Sue-Anne McLachlan,
Benjamin Thomson,
Benjamin Loveday,
Brett Knowles,
Adrian Fox,
Mehrdad Nikfarjam,
Val Usatoff,
Julia Shapiro,
Kate Clarke,
Sharon Pattison,
Cheng Ean Chee,
Rob Zielinski,
Rachel Wong,
Peter Gibbs,
Belinda Lee

摘要

Background

Pancreatic cancer incidence is increasing in younger populations. Differences between early onset pancreatic cancer (EOPC) and later onset pancreatic cancer (LOPC), and how these should inform management warrant exploration in the contemporary setting.

Methods

A prospectively collected multi-site dataset on consecutive pancreatic adenocarcinoma patients was interrogated. Patient, tumour, treatment, and outcome data were extracted for EOPC (≤50 years old) vs LOPC (>50 years old).

Results

Of 1683 patients diagnosed between 2016 and 2022, 112 (6.7%) were EOPC. EOPC more frequently had the tail of pancreas tumours, earlier stage disease, surgical resection, and trended towards increased receipt of chemotherapy in the curative setting compared to LOPC. EOPC more frequently received 1st line chemotherapy, 2nd line chemotherapy, and chemoradiotherapy than LOPC in the palliative setting. Recurrence-free survival was improved for the tail of pancreas EOPC vs LOPC in the resected setting; overall survival was superior for EOPC compared to LOPC across the resected, locally advanced unresectable and metastatic settings.

Conclusions

EOPC remains a small proportion of pancreatic cancer diagnoses. The more favourable outcomes in EOPC suggest these younger patients are overall deriving benefits from increased treatment in the curative setting and increased therapy in the palliative setting.